Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study

Background: Brain metastases reduce survival because therapeutic options are limited. This phase II study evaluated the efficacy of single-agent therapy with alternating weekly, dose-dense temozolomide in pretreated patients with brain metastases prospectively stratified by primary tumor type. Metho...

Descripción completa

Detalles Bibliográficos
Autores principales: Siena, S., Crinò, L., Danova, M., Del Prete, S., Cascinu, S., Salvagni, S., Schiavetto, I., Vitali, M., Bajetta, E.
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2010
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2826096/
https://www.ncbi.nlm.nih.gov/pubmed/19767314
http://dx.doi.org/10.1093/annonc/mdp343

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2826096/
https://www.ncbi.nlm.nih.gov/pubmed/19767314
http://dx.doi.org/10.1093/annonc/mdp343

Ejemplares similares